Showing results (141-150 of 889) with videos related to
Sort By:
Pageof 89
Drugs in R&D|May 7, 2014
Assessment of anti-plasmodial activity of non-hemolytic, non-immunogenic, non-toxic antimicrobial peptides (AMPs LR14) produced by Lactobacillus plantarum LR/14Ruchi Gupta, Vinoth Rajendran, Prahlad C Ghosh, et al.Drugs in R&D|March 23, 2013
Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended releaseBenno Roesch, Mary Corcoran, Mary Haffey, et al.Drugs in R&D|August 6, 2014
A multicenter, open-label study of an intravenous short-acting β1-adrenergic receptor antagonist landiolol hydrochloride for coronary computed tomography angiography by 16-slice multi-detector computed tomography in Japanese patients with suspected ischemic cardiac diseaseMasaharu Hirano, Akira Yamashina, Kazuhiro Hara, et al.Drugs in R&D|August 29, 2013
Describing the profile of patients on concurrent rifampin and warfarin therapy in western Kenya: a case seriesM W Maina, S D Pastakia, I Manji, et al.Drugs in R&D|August 31, 2013
Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic anginaJoseph B Muhlestein, Sharon GrehanDrugs in R&D|September 18, 2013
Inhaler competence and patient satisfaction with Easyhaler®: results of two real-life multicentre studies in asthma and COPDGabriella Gálffy, Györgyi Mezei, Gyula Németh, et al.Drugs in R&D|September 21, 2015
Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of TacrolimusKota Ishida, Katsuhisa Shiraki, Takashi YoshiyasuDrugs in R&D|February 11, 2016
Stability Characterization of a Polysorbate 80-Dimethyl Trisulfide Formulation, a Cyanide Antidote CandidateCraig M Bartling, Jon C Andre, Carrie A Howland, et al.Drugs in R&D|August 20, 2015
Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?Jörg Ruof, Olivier Flückiger, Niko AndrePageof 89